In vitro and patient-derived xenograft (PDX) models of prostate cancer have since found evidence that PTEN and the abnormally spliced ligand independent androgen receptor variant 7 (AR-V7) could have potential use as biomarkers for response to this combination of therapy. The gene discussed is PTEN; the disease is prostate carcinoma.